CoreCap Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

CoreCap Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.89K	Hold	5	–	–	﹤0.01%	2517
2026 Q2	$1.47K	Hold	5	–	–	﹤0.01%	2617
2026 Q1	$1.39K	Hold	5	–	–	﹤0.01%	2477
2025 Q4	$1.52K	Buy	+5	New	+$1.56K	﹤0.01%	2528
2024 Q2	–	Sell	-122	Closed	-$42.2K	–	1712
2024 Q1	$42.2K	Buy	+122	New	+$40.1K	﹤0.01%	1180
2022 Q3	–	Sell	-193	Closed	-$96K	–	697
2022 Q2	$96K	Buy	+193	New	+$101K	0.01%	704

Other funds holding BIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

Focused Alpha LLC Denver, Colorado $402M AUM 23.92% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

CoreCap Advisors's BIO Position: Q3 2026 in Review

CoreCap Advisors held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2026 at 5 shares worth $1.89K. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

CoreCap Advisors first reported a position in BIO in Q2 2022 and has held it in 6 quarters since. The position peaked at $96K in Q2 2022. 65 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

CoreCap Advisors held 5 shares of Bio-Rad Laboratories Class A worth $1.89K as of Q3 2026.
CoreCap Advisors left its Bio-Rad Laboratories Class A share count unchanged in Q3 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2517 holding.
CoreCap Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and has held it in 6 quarters since.
CoreCap Advisors's Bio-Rad Laboratories Class A position peaked at $96K in Q2 2022.
65 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.